BIT Capital GmbH bought a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 53,928 shares of the biopharmaceutical company's stock, valued at approximately $2,114,000. BIT Capital GmbH owned approximately 0.07% of Xenon Pharmaceuticals at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. JPMorgan Chase & Co. grew its stake in shares of Xenon Pharmaceuticals by 38.9% in the 4th quarter. JPMorgan Chase & Co. now owns 1,356,895 shares of the biopharmaceutical company's stock worth $53,190,000 after buying an additional 380,112 shares during the last quarter. Prudential Financial Inc. boosted its stake in Xenon Pharmaceuticals by 177.7% in the 4th quarter. Prudential Financial Inc. now owns 39,000 shares of the biopharmaceutical company's stock worth $1,529,000 after purchasing an additional 24,956 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth approximately $502,000. Magnetar Financial LLC bought a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at $210,000. Finally, Teacher Retirement System of Texas lifted its stake in shares of Xenon Pharmaceuticals by 18.6% in the 4th quarter. Teacher Retirement System of Texas now owns 19,083 shares of the biopharmaceutical company's stock worth $748,000 after purchasing an additional 2,994 shares during the period. 95.45% of the stock is owned by hedge funds and other institutional investors.
Xenon Pharmaceuticals Price Performance
Shares of XENE stock traded down $1.34 during mid-day trading on Monday, hitting $32.92. The stock had a trading volume of 118,515 shares, compared to its average volume of 441,211. The firm has a market capitalization of $2.52 billion, a P/E ratio of -11.67 and a beta of 1.26. Xenon Pharmaceuticals Inc. has a 12-month low of $32.70 and a 12-month high of $46.00. The firm's 50-day moving average is $37.72 and its two-hundred day moving average is $39.74.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.05. Analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.
Insider Activity
In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 22,468 shares of Xenon Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $40.20, for a total value of $903,213.60. Following the completion of the transaction, the chief executive officer now owns 31,302 shares of the company's stock, valued at approximately $1,258,340.40. The trade was a 41.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.52% of the company's stock.
Analyst Ratings Changes
XENE has been the topic of several analyst reports. HC Wainwright reiterated a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, February 24th. Royal Bank of Canada reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, February 11th. They set a "buy" rating and a $67.00 price target on the stock. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. Finally, StockNews.com raised Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $57.38.
View Our Latest Stock Analysis on XENE
Xenon Pharmaceuticals Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Further Reading
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
